Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report 2017 - Novel Treatments Offer a Ray of Hope - Research and Markets

This image opens in the lightbox

News provided by

Research and Markets

26 Apr, 2017, 17:15 GMT

Share this article

Share toX

Share this article

Share toX

DUBLIN, April 26, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Acute Heart Failure (AHF) Therapeutics - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Acute Heart Failure (AHF) Therapeutics in US$ Thousand. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Market data and analytics are derived from primary and secondary research.

The report profiles 34 companies including many key and niche players such as:

  • Bayer AG (Germany)
  • Bristol-Myers Squibb Company (USA)
  • Cardiorentis AG (Switzerland)
  • CVie Therapeutics Limited (Taiwan)
  • Cytokinetics, Inc. (USA)
  • Merck & Co. (USA)
  • Novartis AG (Switzerland)
  • Orion Corporation (Finland)
  • PhaseBio Pharmaceuticals, Inc. (USA)

Key Topics Covered:

1. INDUSTRY OVERVIEW

  • Market Outlook
  • Acute Heart Failure - An Overview of the Disease and Available Therapeutics
  • Diuretics and Vasodilators - The First Line Therapy for AHF
  • Select Key Diuretics for AHF Treatment by Dosage and Route of Administration
  • Comparison of Most Common Vasodilators Used in ADHF Treatment
  • Other Known Drugs for AHF - Lower Efficacy Thwarts Use
  • Comparison of Select Inotropic Therapies for Acute Heart Failure Treatment
  • Standard Approved AHF Therapeutics as per Agency Guidelines

2. MARKET DRIVERS, TRENDS & ISSUES

  • Conventional Therapies Leave Considerable Unmet Needs
  • Novel Treatments Offer a Ray of Hope
  • Key AHF Therapeutics in the Pipeline
  • Serelaxin Nears Trial Readout form RELAX-AHF-2
  • Ularitide - A Novel Drug in Development for AHF
  • Ularitide's Fate Hangs in Balance
  • Impact of Ularitide's Clinical Trial Outcomes
  • The Litany of Drug Failures Expands, Emphasis on Prevention Grows
  • Failure of TRV027 - A Disappointment
  • Other Promising Drugs under Development
  • CAP-1002 (Capricor Therapeutics, Inc.)
  • Istaroxime (CVie Therapeutics)
  • PB-1046 (PhaseBio Pharmaceuticals)
  • omecamtiv mecarbil (Cytokinetics & Amgen)
  • CXL-1427 (Bristol Myers Squibb)
  • Research Findings
  • Kidney Dysfunction - Predictor of Acute Heart failure
  • Genetic Influence on Heart Disease among African Americans
  • Higher Body Mass Index - A Key Risk Factor for AHF
  • Supplemental Oxygen Therapy May not be for All Cases of AHF
  • Macro Growth Drivers
  • Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics

3. TREATMENT OF ACUTE HEART FAILURE (AHF)

  • Acute Decompensated Heart Failure Treatment by Type and Action Mechanism
  • A Review of Drug Classes
  • ACE Inhibitors
  • Aldosterone Antagonists
  • Angiotensin II Receptor Blockers (ARBs)
  • ß-Blockers
  • Calcium Channel Blockers
  • Cardiac Glycosides
  • Diuretics
  • Dosage of Diuretics Used in the Treatment of AHF
  • Inotropic Agents
  • Digoxin (Lanoxin)
  • Morphine
  • Vasodilators/Nitrates
  • Vasodilators Used in AHF Treatment: Type, Indications for Use and Side Effects
  • Drug Tolerance of Patients Based on Signs and Symptoms
  • Treatment on the Basis of Adverse Signs
  • Oliguria/Anuria (Cardiorenal Syndrome)
  • Drowsiness/Confusion
  • Hypotension (systolic BP<_0mmhg_ />
  • Persistent Pulmonary Edema
  • Lifestyle Changes

4. ACUTE HEART FAILURE - THE DISEASE, CAUSES, SYMPTOMS, AND EVALUATION METHODS

  • Types of AHF
  • Causes of AHF
  • Coronary Heart Disease
  • Cardiomyopathy
  • High BP
  • Damaged Heart Valves
  • Patho-Physiology of AHF
  • Signs and Symptoms
  • Low Output
  • Fluid Overload/Congestion
  • Left-Sided Failure
  • Right-Sided Failure
  • Biventricular Failure
  • Diagnosis
  • Classification of AHF
  • Left Side and Right Side
  • Systolic Dysfunction and Diastolic Dysfunction
  • Backward and Forward Failure
  • Low-Output Heart Failure and High-Output Heart Failure
  • Functional Classification
  • By NYHA
  • By American College of Cardiology/American Heart Association
  • Phases of Evaluation and Management of AHF Patients
  • Early/Initial Phase
  • In-Hospital Phase
  • Pre-Discharge Phase
  • Early Post-Discharge Phase

5. RECENT INDUSTRY ACTIVITY

  • Capricor Terminates Licensing Deal for Cenderitide with Mayo Clinic
  • Renova Acquires Stresscopin from Janssen
  • Cytokinetics to Sell Part of Potential Royalty on omecamtiv mecarbil to Royalty Pharma
  • CVie Therapeutics Enrolls First Patient for Phase 2b Clinical Trial of Istaroxime
  • ScinoPharm and CVie Therapeutics Collaborate for New AHF Drug
  • Trevena's TRV027 Fails to Meet Clinical Study Endpoints
  • NIH Awards SBIR Grant to Madeleine Pharmaceuticals for Clinical Development of Vastiras®
  • Cardiorentis Raises Funds to Support Competition of Phase III Trials on Ularitide for ADHF
  • FDA Grants Fast Track Designation to Cardiorentis' Ularitide
  • Bristol-Myers Squibb Completes Acquisition of Cardioxyl
  • Cardiorentis Completes Enrollment in Phase III Trial of Ularitide
  • Capricor Therapeutics Completes Enrollment for Phase II Trial of Cenderitide
  • Cardiorentis Enters into Collaboration with Roche
  • Capricor Enters into Agreement to Acquire Patent Rights of Natriuretic Peptides from Medtronic
  • Cardiorentis Enters into 45 million Financing Agreement with HC Royalty
  • USPTO Grants Patent to Trevena's TRV027
  • FDA Declines Approval for Novartis' Serelaxin

6. FOCUS ON SELECT PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 34 (including Divisions/Subsidiaries - 35)

- The United States (18)
- Japan (2)
- Europe (10)

- Germany (2)
- The United Kingdom (2)
- Italy (1)
- Rest of Europe (5)

- Asia-Pacific (Excluding Japan) (5)

For more information about this report visit http://www.researchandmarkets.com/research/9nm929/acute_heart

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.